Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EMA accepts Thrombogenics' MAA for ocriplasmin for retinal disease

This article was originally published in Scrip

Executive Summary

The European Medicines Agency (EMA) has accepted for review Thrombogenics' marketing authorisation application (MAA) for ocriplasmin (2.5 mg/ml, solution for injection) for the treatment of symptomatic vitreomacular adhesion (VMA) including macular hole. Ocriplasmin's MAA will be evaluated through the EMA's centralised procedure with an official start date of 19 October 2011 and, if approved, the product will gain marketing authorisation for all EU Member States simultaneously. Successful approval will make it the first pharmacological treatment for this indication.

Advertisement

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC014901

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel